1. Home
  2. CRDL vs DOGZ Comparison

CRDL vs DOGZ Comparison

Compare CRDL & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

DOGZ

Dogness (International) Corporation

HOLD

Current Price

$0.94

Market Cap

153.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDL
DOGZ
Founded
2017
2003
Country
Canada
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Miscellaneous manufacturing industries
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
132.6M
153.5M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
CRDL
DOGZ
Price
$1.31
$0.94
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
935.4K
25.3K
Earning Date
05-14-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.81
52 Week High
$1.71
$16.59

Technical Indicators

Market Signals
Indicator
CRDL
DOGZ
Relative Strength Index (RSI) 63.70 49.48
Support Level $0.95 $0.86
Resistance Level $1.36 $1.06
Average True Range (ATR) 0.10 0.10
MACD 0.01 0.00
Stochastic Oscillator 95.96 72.51

Price Performance

Historical Comparison
CRDL
DOGZ

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

Share on Social Networks: